I don't think it's funny unless you find giving the legal department more work to be funny. Seriously, I think Teva knows this CP will be rejected. The purpose seems to be discussing the five criteria from generic Lovenox approval with regard to Copaxone and also asking for an advisory committee.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.